Evidence map›Paper›PMID 37311510›Full record

Trial reportTransplantation and cellular therapy2023

Phase II Study of Myeloablative 7-8/8-Matched Allotransplantation with Post-Transplantation Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil.

Najla El Jurdi, Alex Hoover, Daniel O'Leary, Qing Cao, Ashish Gupta, Christen Ebens, Joseph E Maakaron, Brian C Betts, Armin Rashidi, Mark B Juckett and 11 more

Open access · hybridAbstract readClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Transplantation and cellular therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
5.5field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Potential of Fecal Microbiota Transplantation to Prevent Acute GVHD: Analysis from a Phase II Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2023
    Trial
  5. Article
  6. New age GVHD prophylaxis regimens: what works for what donor and why.Hematology. American Society of Hematology. Education Program · 2025
    Review
  7. New age HCT conditioning regimens: what works and why?Hematology. American Society of Hematology. Education Program · 2025
    Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Novel approaches to acute graft-versus-host disease prevention.Hematology. American Society of Hematology. Education Program · 2023
    Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 1 institution in 1 country.

Najla El JurdiDivision of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota.
Alex HooverDivision of Pediatric Hematology/Oncology, University of Minnesota, Minneapolis, Minnesota.
Daniel O'LearyDivision of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota.
Qing CaoBiostatistics Core, Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota.
Ashish GuptaDivision of Pediatric Blood and Marrow Transplant & Cellular Therapy, University of Minnesota, Minneapolis, Minnesota.
Christen EbensDivision of Pediatric Blood and Marrow Transplant & Cellular Therapy, University of Minnesota, Minneapolis, Minnesota.
Joseph E MaakaronDivision of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota.
Brian C BettsDivision of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota.
Armin RashidiDivision of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota.
Mark B JuckettDivision of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota.
Troy LundDivision of Pediatric Blood and Marrow Transplant & Cellular Therapy, University of Minnesota, Minneapolis, Minnesota.
Veronika BachanovaDivision of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota.
Margaret L MacMillanDivision of Pediatric Blood and Marrow Transplant & Cellular Therapy, University of Minnesota, Minneapolis, Minnesota.
Jeffrey S MillerDivision of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota.
Paul J OrchardDivision of Pediatric Blood and Marrow Transplant & Cellular Therapy, University of Minnesota, Minneapolis, Minnesota.
John E WagnerDivision of Pediatric Blood and Marrow Transplant & Cellular Therapy, University of Minnesota, Minneapolis, Minnesota.
Gregory VercellottiDivision of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota.
Daniel J WeisdorfDivision of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota.
Kathryn DusenberyDepartment of Radiation Oncology, University of Minnesota, Minneapolis, Minnesota.
Stephanie TerezakisDepartment of Radiation Oncology, University of Minnesota, Minneapolis, Minnesota.
Shernan G HoltanDivision of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, Minnesota. Electronic address: sgholtan@umn.edu.
University of Minnesota · US

Funding

Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Timothy C. Hallstrom · 1998 to 2026
$100.4M
Trial Design and Biostatistical Support CoreP01CA065493 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Mark J Osborn · 1995 to 2026
$48.2M
University of Minnesota Clinical and Translational Science Institute (UMN CTSI)UL1TR002494 · NCATS · UNIVERSITY OF MINNESOTA · PI BLAZAR, BRUCE R, WEISDORF, DANIEL J · 2018 to 2022
$34.9M
Translational Pediatric Cancer Epidemiology Research Training GrantT32CA099936 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Logan G. Spector · 2004 to 2026
$5.1M
NCATS NIH HHS UL1 TR002494NCI NIH HHS P01 CA065493NCI NIH HHS P30 CA077598NCI NIH HHS T32 CA099936
6 · The paper itself

Abstract

Graft-versus-host disease (GVHD) is the major toxicity of allogeneic hematopoietic cell transplantation (HCT). We hypothesized that a GVHD prophylaxis regimen of post-transplantation cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolate mofetil (MMF) would be associated with incidences of acute and chronic GVHD in patients receiving a matched or single antigen mismatched HCT. This Phase II study was conducted at the University of Minnesota using a myeloablative regimen of either total body irradiation (TBI) at a total dose of 1320 cGy, administered in 165-cGy fractions, twice daily from day -4 to day -1, or busulfan (Bu) 3.2 mg/kg daily (cumulative area under the curve, 19,000 to 21,000 μmol/min/L) plus fludarabine (Flu) 40 mg/m

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationAdultBusulfanChildCyclophosphamideHumansMycophenolic AcidTacrolimusBusulfanCyclophosphamideMycophenolic AcidTacrolimusAllogeneicGraft-versus-host diseaseMyeloablativePost-transplantation cyclophosphamide

Identifiers

PMID37311510
PMCPMC10530433
OpenAlexW4380268846

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.